Beta-Lactamase Inhibitor - Pipeline Insight, 2024

Beta-Lactamase Inhibitor - Pipeline Insight, 2024

DelveInsight’s, “Beta-Lactamase Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Beta-Lactamase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Beta-Lactamase Inhibitor Understanding

Beta-Lactamase Inhibitor: Overview

Beta-lactamases are an important group of bacterial enzymes, which preferentially cleave the beta-lactam ring of penicillins, cephalosporins, or other medically important beta-lactam antibiotics.

Function - Beta-lactamase provides antibiotic resistance by breaking the antibiotics' structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a β-lactam. Through hydrolysis, the enzyme lactamase breaks the β-lactam ring open, deactivating the molecule's antibacterial properties.

Beta-Lactamase Inhibitors - Beta-lactamase inhibitors are drugs that are co-administered with beta-lactam antimicrobials to prevent antimicrobial resistance by inhibiting serine beta-lactamases, which are enzymes that inactivate the beta-lactam ring, which is a common chemical structure to all beta-lactam antimicrobials. This activity outlines the different types of beta-lactamase inhibitors.

Beta-Lactamase Inhibitor Emerging Drugs Chapters

This segment of the Beta-Lactamase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Beta-Lactamase Inhibitor Emerging Drugs

• Durlobactam/sulbactam: Entasis Therapeutics

Durlobactam (DUR; previously designated ETX2514) is a novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. The company is developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains. Currently, it is in phase 3 stage of development for the treatment of Acinetobacter infections.

• Ceftibuten/VNRX 7145: VenatoRx Pharmaceuticals

VNRX-7145, an orally bioavailable beta-lactamase inhibitor (BLI) that in a fixed combination with the third generation orally bioavailable cephalosporin, ceftibuten, has the potential to rescue activity of the partner antibiotic against extended spectrum beta-lactamases (ESBLs) and key carbapenem-resistant Enterobacterales (CRE), including those expressing Klebsiella pneumoniae carbapenemase (KPC) and Oxacillinase (OXA) carbapenemases.

Further product details are provided in the report……..

Beta-Lactamase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Beta-Lactamase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Beta-Lactamase Inhibitor

There are approx. 12+ key companies which are developing the Beta-Lactamase Inhibitor. The companies which have their Beta-Lactamase Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Entasis Therapeutics.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Beta-Lactamase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beta-Lactamase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta-Lactamase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta-Lactamase Inhibitor drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Beta-Lactamase Inhibitor R&D. The therapies under development are focused on novel approaches for Beta-Lactamase Inhibitor.

Beta-Lactamase Inhibitor Report Insights

• Beta-Lactamase Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Beta-Lactamase Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Beta-Lactamase Inhibitor drugs?
• How many Beta-Lactamase Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Beta-Lactamase Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta-Lactamase Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Beta-Lactamase Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Entasis Therapeutics
• VenatoRx Pharmaceuticals
• Qpex Biopharma
• Boston Pharmaceuticals
• Merck Sharp and Dohme
• Fedora Pharmaceuticals
• Allecra Therapeutics
• AbbVie
• Arixa Pharmaceuticals
• LegoChem Biosciences
• Yuhan
• Allergan
• AstraZeneca
• Antabio
• Infex Therapeutics

Key Products

• Durlobactam/sulbactam
• Ceftibuten/VNRX 7145
• QPX 7728
• BOS 572
• MK-7655A
• Nacubactam
• AAI-202
• ATM-AVI
• ARX 1796
• LCB18 0055
• YH-1177D
• CEF-104
• ANT2681